stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Operating cash flow
Harmony Biosciences Holdings, Inc.'s operating cash flow for fiscal 2025 was $348.2M, up 58.4% from $219.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $323.0M. Over the past ten years it has ranged from −$75.4M (fiscal 2019) to $348.2M (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 6 consecutive fiscal years. Harmony Biosciences Holdings, Inc. ranks 17th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $348.2M | 58.40% |
| FY2024 | $219.8M | 0.20% |
| FY2023 | $219.4M | 51.86% |
| FY2022 | $144.5M | 46.58% |
| FY2021 | $98.6M | — |
| FY2020 | −$3.0M | — |
| FY2019 | −$75.4M | — |
| FY2018 | −$38.8M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $76.7M | (17.03%) |
| Jun 2026 | $92.4M | 232.97% |
| Mar 2026 | $27.8M | (77.99%) |
| Dec 2025 | $126.2M | 16.02% |
| 26 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. | $323.0M |
| FTRE Fortrea Holdings Inc. compare | $201.8M |
| SRPT Sarepta Therapeutics, Inc. compare | $185.6M |
| TRVI Trevi Therapeutics, Inc. compare | −$52.6M |
| MESO Mesoblast Limited compare | −$83.5M |
| MAZE Maze Therapeutics, Inc. compare | −$106.5M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.2M |
| VIR Vir Biotechnology, Inc. compare | −$141.0M |
| REPL Replimune Group, Inc. compare | −$245.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item